ARTICLE | Company News
Genentech gains its first U.S. tissue-agnostic approval with Rozlytrek
August 15, 2019 10:33 PM UTC
Following a Japanese approval in June, Roche’s Genentech unit scored accelerated approval in the U.S. Thursday for its Rozlytrek entrectinib to treat NTRK fusion-positive solid tumors.
FDA also approved the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK to treat ROS1-positive, metastatic non-small cell lung cancer...
BCIQ Target Profiles